Subsidised non-insulin medications for Type 2 Diabetes Mellitus

Published on 17 May 2023
Last Updated on 16 December 2024

The Ministry of Health (MOH) provides subsidies for drugs at our public hospitals, specialist outpatient clinics and polyclinics to ensure that patients have access to effective medications for common medical conditions in Singapore.

The drug availability at each healthcare institution varies, depending on the clinical conditions commonly managed by the institution and the drugs usually prescribed by the doctors. The general drug availability in public healthcare institutions* can be found in the individual drug monographs at the National Drug Formulary webpage, if available.

Active Ingredient(s)	Strength(s)	Subsidy Class[†]	Clinical Indication of Subsidy (where applicable)
Biguanide			
Metformin[‡]	250mg, 500mg, 850mg	SDL	-
DPP-4 inhibitor (DPP-4i)			
Linagliptin	5mg	MAF	For patients with type 2 diabetes mellitus and chronic kidney disease stages 3b, 4 or 5
Sitagliptin	25mg, 50mg, 100mg	SDL	-
GLP-1 receptor agonist (GLP-1 RA)			
Dulaglutide	0.75mg/0.5mL, 1.5mg/0.5mL	MAF	For the treatment of type 2 diabetes mellitus 1) As a triple therapy in combination with two oral anti-diabetic drug (OAD) therapies for patients with inadequate glycaemic control despite treatment with optimal doses of dual OAD therapy, or as a dual therapy in combination with one OAD therapy if a dual OAD therapy is contraindicated or not tolerated 2) In combination with insulin and metformin, unless metformin is contraindicated or not tolerated
Sodium-glucose cotransporter 2 inhibitor (SGLT2i)			
Empagliflozin	10mg, 25mg	SDL	-
Sulfonylurea			
Glibenclamide	5mg	SDL	-
Gliclazide[§]	80mg	SDL	-
Glipizide	5mg	SDL	-
Tolbutamide	500mg	SDL	-

* Based on public healthcare institutions formulary listing.
[†] SDL refers to the Standard Drug List and MAF refers to the Medication Assistance Fund.
[‡] The extended-release formulation is not subsidised.
[§] The modified-release formulation is not subsidised.